查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790408

Eliquis（Apixaban）市场规模、份额和趋势分析报告：按适应症、分销管道、地区和细分市场预测，2025 年至 2033 年

Eliquis (Apixaban) Market Size, Share & Trends Analysis Report By Indication (Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

Eliquis（Apixaban）市场摘要

2024 年全球 Eliquis（Apixaban）市值估计为 207 亿美元，预计到 2033 年将达到 188.7 亿美元，2025 年至 2033 年的复合年增长率为 -2.2%。这一成长主要受专利独占权的丧失、学名药竞争加剧以及主要市场价格下降的推动。

全球心房颤动 (AF) 和静脉血栓栓塞症(VTE) 负担日益加重，已成为 Eliquis（Apixaban）市场的主要驱动力。由于 AF 显着增加中风风险，使用抗凝血剂进行长期预防的现象正在增加。 2022 年 6 月，《临床医学杂誌》发表了统合分析，评估了Apixaban的安全性和有效性。研究发现，与其他抗凝血剂相比，Apixaban表现出良好的疗效，中风、死亡和大出血风险较低。 Eliquis 良好的安全性和最低的监测要求使其成为首选。循环系统实践指南扩大了直接口服抗凝血剂的使用，导致其在基层医疗和专科护理中广泛应用。随着 AF 和 VTE 病例的增加，尤其是在老化人口中，对像 Eliquis 这样可靠、易于管理的抗凝血剂的需求持续增长。

临床实务向直接口服抗凝血剂的转变正在巩固 Eliquis 的市场地位。医疗保健提供者重视直接口服抗凝血剂 (DOAC)，因为其药物动力学可预测、剂量固定，且与Warfarin相比，发生严重出血事件的风险较低。 Eliquis 在大型试验中表现出色，并有助于提高全球处方率。患者受益于简化的治疗方法，可提高依从性并减少就诊次数。随着从传统抗凝血剂向 DOAC 的转变加速，Eliquis 已做好准备，扩大其在全球抗凝血剂市场的份额。

目录

第一章调查方法与范围

第二章执行摘要

第三章 Eliquis（Apixaban）市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章 Eliquis（Apixaban）市场：适应症业务分析

  • 2024年及2033年指示市场占有率
  • 指示细分仪表板
  • 市场规模、预测与趋势分析（按适应症，2021-2033 年）
  • 心房颤动（AF）
  • 深层静脉栓塞症（DVT）
  • 肺动脉栓塞（PE）
  • 术后静脉血栓栓塞症（VTE）预防
  • 其他的

第五章 Eliquis（Apixaban）市场：分销通路业务分析

  • 2024年及2033年分销通路市场占有率
  • 分销通路细分仪表板
  • 市场规模、预测与趋势分析（按分销管道，2021-2033 年）
  • 医院药房
  • 零售药局
  • 网路药局

第六章 Eliquis（Apixaban）市场：区域估计与趋势分析

  • 2024 年及 2033 年区域市场占有率分析
  • 区域市场仪表板
  • 2021-2033年市场规模与预测趋势分析
  • 北美洲
    • 按国家/地区，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • F. Hoffmann-La Roche Ltd.
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Pfizer Inc.
    • GSK plc
    • Novartis AG
    • AstraZeneca
    • Johnson &Johnson Private Limited
    • Bristol-Myers Squibb Company
Product Code: GVR-4-68040-673-0

Eliquis (Apixaban) Market Summary

The global Eliquis (apixaban) market size was estimated at USD 20.70 billion in 2024 and is projected to reach USD 18.87 billion by 2033, with a decline of CAGR of -2.2% from 2025 to 2033, primarily due to loss of patent exclusivity, growing generic competition, and consequent price erosion across major markets.

The increasing global burden of atrial fibrillation (AF) and venous thromboembolism (VTE) has emerged as a major driver for the Eliquis (Apixaban) market. AF significantly raises the risk of stroke, prompting greater use of anticoagulants for long-term prevention. In June 2022, the Journal of Clinical Medicine published a meta-analysis of over 3.9 million adults with atrial fibrillation, assessing apixaban's safety and effectiveness. The study found that apixaban had favorable outcomes compared to other anticoagulants, with lower stroke risks, mortality, and major bleeding. Eliquis has become a preferred option due to its favorable safety profile and minimal need for monitoring. Clinical guidelines in cardiology have expanded the use of direct oral anticoagulants, leading to broader adoption across primary and specialty care. As AF and VTE cases rise, particularly among aging populations, the demand for reliable and easy-to-administer anticoagulants such as Eliquis continues to grow.

Shifts in clinical practice toward direct oral anticoagulants have strengthened Eliquis's market position. Healthcare providers value DOACs for their predictable pharmacokinetics, fixed dosing, and lower risk of major bleeding events than warfarin. Eliquis has shown superior results in large-scale trials, contributing to its high prescription rates worldwide. Patients benefit from simplified treatment regimens that improve adherence and reduce healthcare visits. As transitioning from traditional anticoagulants to DOACs accelerates, Eliquis is well-positioned to capture a growing share of the global anticoagulant market.

Global Eliquis (Apixaban) Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Eliquis (apixaban) market report based on indication, distribution channel, and region:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Atrial Fibrillation (AF)
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Post-Operative Venous Thromboembolism (VTE) Prophylaxis
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Eliquis (Apixaban) Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Eliquis (Apixaban) Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 4.4. Atrial Fibrillation (AF)
    • 4.4.1. Atrial Fibrillation (AF) Market, 2021 - 2033 (USD Million)
  • 4.5. Deep Vein Thrombosis (DVT)
    • 4.5.1. Deep Vein Thrombosis (DVT) Market, 2021 - 2033 (USD Million)
  • 4.6. Pulmonary Embolism (PE)
    • 4.6.1. Pulmonary Embolism (PE) Market, 2021 - 2033 (USD Million)
  • 4.7. Post-Operative Venous Thromboembolism (VTE) Prophylaxis
    • 4.7.1. Post-Operative Venous Thromboembolism (VTE) Prophylaxis Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Eliquis (Apixaban) Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.6. Online Pharmacies
    • 5.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 6. Eliquis (Apixaban) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Eliquis (Apixaban) Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Distribution Channel Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Distribution Channel Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Distribution Channel Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Distribution Channel Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Distribution Channel Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Distribution Channel Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Distribution Channel Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Distribution Channel Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Distribution Channel Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Distribution Channel Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Distribution Channel Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Distribution Channel Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Distribution Channel Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Distribution Channel Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Distribution Channel Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Distribution Channel Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Distribution Channel Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Distribution Channel Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Distribution Channel Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Distribution Channel Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Distribution Channel Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Distribution Channel Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Distribution Channel Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. F. Hoffmann-La Roche Ltd.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Mylan NV
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Teva Pharmaceutical Industries Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Sanofi
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Pfizer Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. GSK plc
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Novartis AG
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. AstraZeneca
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Johnson & Johnson Private Limited
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Bristol-Myers Squibb Company
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Eliquis (apixaban) market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 5 Global Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6 North America Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 8 North America Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9 U.S. Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 10 U.S. Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 Canada Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 12 Canada Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 Mexico Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 14 Mexico Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15 Europe Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 17 Europe Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18 UK Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 19 UK Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Germany Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 21 Germany Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22 France Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 23 France Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 Italy Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 25 Italy Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26 Spain Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 27 Spain Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 Norway Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 29 Norway Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 Denmark Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 31 Denmark Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32 Sweden Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 33 Sweden Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific Eliquis (apixaban) market, by indication, 2021 - 2033 (USD
  • Table 36 Asia Pacific Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37 Japan Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 38 Japan Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 China Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 40 China Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41 India Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 42 India Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43 Australia Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 44 Australia Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 South Korea Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 46 South Korea Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47 Thailand Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 48 Thailand Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49 Latin America Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 51 Latin America Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Brazil Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 53 Brazil Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Argentina Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 55 Argentina Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59 South Africa Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 60 South Africa Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63 UAE Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 64 UAE Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Kuwait Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 66 Kuwait Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Eliquis (apixaban) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Eliquis (apixaban) market dynamics
  • Fig. 12 Eliquis (apixaban) market: Porter's five forces analysis
  • Fig. 13 Eliquis (apixaban) market: PESTLE analysis
  • Fig. 14 Indication market, 2021 - 2033 (USD Million)
  • Fig. 15 Atrial Fibrillation (AF) market, 2021 - 2033 (USD Million)
  • Fig. 16 Deep Vein Thrombosis (DVT) market, 2021 - 2033 (USD Million)
  • Fig. 17 Pulmonary Embolism (PE) market, 2021 - 2033 (USD Million)
  • Fig. 18 Post-Operative Venous Thromboembolism (VTE) Prophylaxis market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 21 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 22 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 23 Online Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 24 Eliquis (apixaban) market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 33 Europe Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 50 Asia Pacific Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 63 Latin America Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 68 MEA Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework